Why the study?
Do metoprolol plasma concentrations or CYP2D6 genotypes predict adverse events or efficacy in patients with hypertension?
Population
50 patients with hypertension
Comparison
Metoprolol administered via a dose-titration… vs Different CYP2D6 genotypes/phenotypes and…
Design
Cohort
Authors
Loading...
Does not support routine CYP2D6 testing or concentration monitoring for metoprolol in hypertension; hypothesis-generating for larger prospective studies.
Do metoprolol plasma concentrations or CYP2D6 genotypes predict adverse events or efficacy in patients with hypertension?
CYP2D6 genotype and metoprolol plasma concentrations do not predict adverse effects or antihypertensive efficacy, suggesting routine pharmacogenetic testing for metoprolol in hypertension may not be clinically useful.
Zineh et al. (2004) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: